CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 115 enrolled
Drug / intervention
Irbesartan +1 moredrug
Likely dose
Irbesartan 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00389168
NCT00389168Phase 3Completed

Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy

Karolinska Institutet·interventional·Posted Oct 18, 2006·Updated May 5, 2015

In Brief

A Phase 3 clinical trial evaluating Irbesartan and Atenolol for Hypertension. Completed, enrolled 115 participants across 1 site.

Detailed Summary

The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSweden

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 18, 2006
Enrollment StartApr 1, 1995
Primary CompletionApr 1, 1997
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.7 years ago

Interventions

Irbesartandrug

Titrated to 300 mg od, 48 weeks.

Atenololdrug

Titrated to 100 mg od, 48 weeks.